Dexmethylphenidate is a norepinephrine-dopamine reuptake inhibitor used in the treatment of ADHD in conjunction with other therapies. Dexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002.
- Mechanism
- Curator reviewed · 3 references
Methylphenidate inhibits dopamine and norepinephrine reuptake transporters in synapses, especially in the thalamus and striatum. One study shows no detectable difference in the caudal prefrontal cortex of treated or untreated monkeys, though multiple rat studies show activity on the prefrontal cortex. Imaging of human brains after administration of methylphenidate shows changes to blood flow of various regions of the brain including the striatum, supplementary motor area, and posterior parietal cortex.
- Primary indication
- Dexmethylphenidate is used as a treatment for ADHD, ideally in conjunction with psychological, educational, behavioral or other forms of treatment.Curator reviewed · 1 structured indication
- Formula / weight
- C14H19NO2 · 233.3062 g/mol (avg)
- First approval
- Canada, 2003 · United States, 2001
- Also known as
- d-threo-methylphenidate · D-TMP
- Code names
- CTx-1301
- Brand names
Resolves to
DUGOZIWVEXMGBE-CHWSQXEVSA-NSMILES[H][C@@](C(=O)OC)(C1=CC=CC=C1)[C@@]1([H])CCCCN1What you can answer from here — as of September 23, 2026
Which drugs share a target with Dexmethylphenidate, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account